Atai Beckley N.V. (ATAI) Receives Buy Rating on BPL-003 Edge against Spravato

Atai Beckley NV (NASDAQ:ATAI) is a must-buy penny stock to buy now. On November 12, TD Cowen’s Ritu Baral reaffirmed a Buy rating on Atai Beckley NV (NASDAQ:ATAI), pointing to encouraging clinical progress and solid financial footing. Positive Phase 2b results for BPL‑003 in treatment‑resistant depression, a favorable safety profile, and the choice of an 8mg dose for Phase 3 trials strengthen confidence in the program. With a cash runway extending to 2029, recent equity financing, expected FDA feedback, and the merger with Beckley, ATAI is seen as well‑positioned for growth, supporting Baral’s bullish stance.

Source: Pexels

On the same day, ATAI Life Sciences reported third‑quarter revenue of $749,000, far above expectations of $55,560, while unveiling the formation of AtaiBeckley to strengthen its position in next‑generation mental health therapies. The FDA’s Breakthrough Therapy designation for BPL‑003 marked a key milestone in treating resistant depression, supported by positive Phase 2a and 2b results ahead of pivotal development discussions.

The Phase 2b open-label extension (OLE) study for BPL-003 showed sustained and enhanced responses. The candidate drug achieved remission and response rates of 67% and 81%, respectively, by day 57. Following the positive trial results, management remains confident that BPL-003 can be integrated into existing patient care frameworks.

The fact that patients using BPL-003 were discharged within two hours highlights the promising prospects of the candidate drug compared to Spravato. The results emphasize the drug’s advantageous clinical profile as management plans to guide the Phase 3 trial.

ATAI also advanced its pipeline with full enrollment in the EMP‑01 Phase 2a study for social anxiety, expanded trial sites for VLS‑01, and secured a NIDA grant to explore 5‑HT2A/2C receptor agonists for opioid use disorder. Backed by fresh financing, the company remains focused on driving innovation and reshaping mental health treatment.

Atai Beckley NV (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel mental health treatments. Its pipeline of therapies includes psychedelic-based drugs, designed to treat conditions like depression and anxiety.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This article is originally published at Insider Monkey.